Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.500
-0.010 (-0.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $112.76 million as of December 5, 2025. Its market cap has decreased by -16.09% in one year.
Market Cap
112.76M
Enterprise Value
35.44M
1-Year Change
-16.09%
Ranking
Category
Stock Price
$1.50
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $112.76M, an increase of 12.25%. That is a compound annual growth rate of 2.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 5, 2025 | 112.76M | -48.36% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 925.43B |
| Johnson & Johnson | 494.70B |
| AbbVie | 406.92B |
| UnitedHealth Group | 307.72B |
| AstraZeneca | 283.29B |
| Novartis AG | 257.47B |
| Merck & Co. | 253.84B |
| Thermo Fisher Scientific | 218.08B |